Colorectal Cancer

Edward Chu, MD, MMS, has been named director of Albert Einstein Cancer Center.

A recent report found that most patients prefer the Epi proColon blood test for colorectal cancer screening over fecal immunochemical tests and colonoscopy screening. It was the top story in gastroenterology last week.

A study published in the Journal of the National Cancer Institute concludes that Epi proColon is the test of choice for individuals not willing to participate in fecal immunochemical tests or colonoscopy screening.

Colorectal cancer screening rates have significantly decreased in recent years among at-risk populations, and COVID-19 has exacerbated this decline, according to a recent analysis. It was the top story in gastroenterology last week.

Mailed stool blood tests and follow-up phone calls are examples of effective strategies that increased colorectal cancer screening among African Americans, according to findings of a systematic review.

Investigators found differences in incidence of gastric adenocarcinoma in specific anatomic sites among certain racial and ethnic groups aged 50 years and older, according to results published in Gastroenterology.

Colorectal cancer screening rates in recent years have significantly decreased in at-risk groups such patients aged 50 to 52 years and patients under 50 years with Crohn’s disease and ulcerative colitis, according to data collected by the Blue Cross Blue Shield Association and reported in The Health of America report, Rise in Chronic Conditions is Putting More Americans at risk for Colorectal Cancer.

Individuals who received live phone calls were more likely to complete a mailed fecal immunochemical test than those who received a text message, according to study results.

In this exclusive video, Corey A. Siegel, MD, MS, director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and co-founder of ColonaryConcepts, discusses the company’s edible colonoscopy prep that comes in the form of bars and smoothies.

After dysplasia resection in patients with inflammatory bowel disease, risk for colorectal cancer was low, according to results published in Gastrointestinal Endoscopy.